Cargando…
Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820264/ https://www.ncbi.nlm.nih.gov/pubmed/35140461 http://dx.doi.org/10.2147/IJN.S339046 |
_version_ | 1784646192823533568 |
---|---|
author | Steckiewicz, Karol P Cieciórski, Piotr Barcińska, Ewelina Jaśkiewicz, Maciej Narajczyk, Magdalena Bauer, Marta Kamysz, Wojciech Megiel, Elżbieta Inkielewicz-Stepniak, Iwona |
author_facet | Steckiewicz, Karol P Cieciórski, Piotr Barcińska, Ewelina Jaśkiewicz, Maciej Narajczyk, Magdalena Bauer, Marta Kamysz, Wojciech Megiel, Elżbieta Inkielewicz-Stepniak, Iwona |
author_sort | Steckiewicz, Karol P |
collection | PubMed |
description | PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs. MATERIALS AND METHODS: AgNPs were synthesized and characterized by transmission electron microscopy, UV-vis spectrometry, thermogravimetric analyses, and dynamic light scattering. We determined the safety and the antimicrobial and anti-inflammatory properties of synthesized AgNPs in an in vitro model of periodontitis. Antimicrobial properties were determined by measuring the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) on reference strains of bacteria and fungi. Human gingival fibroblast (HGF-1), murine macrophage (RAW264.7) and human foetal osteoblast (hFOB1.19) cells were used in the study. Lipopolysaccharide (LPS) was used to induce inflammation. Cytokine levels were measured using an enzyme-linked immunosorbent assay; metalloproteinase expression was measured using Western blotting. RESULTS: The synthesized AgNPs were spherical and narrow-dispersed with an average diameter of 13.4 nm ± 3.0 nm in the case of AgNPs-CHL and 3.72 nm ± 0.72 nm in the case of AgNPs-PEG-MET. Both types of AgNPs were active against bacteria and fungi. AgNPs-CHL proved to be a more potent antimicrobial agent, although they were more cytotoxic than AgNPs-PEG-MET; however, both demonstrated beneficial properties in nontoxic concentrations. AgNPs-CHL and AgNPs-PEG-MET decreased the production of proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Both agents also decreased the levels of metalloproteinases MMP3 and MMP8, which may indicate that they will inhibit tissue degradation. CONCLUSION: AgNPs-CHL and AgNPs-PEG-MET may be possible therapeutic options for PD, as they have antibacterial and anti-inflammatory properties. However, to fully understand the potential of AgNPs, our in vitro findings must be evaluated in an in vivo model. |
format | Online Article Text |
id | pubmed-8820264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-88202642022-02-08 Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis Steckiewicz, Karol P Cieciórski, Piotr Barcińska, Ewelina Jaśkiewicz, Maciej Narajczyk, Magdalena Bauer, Marta Kamysz, Wojciech Megiel, Elżbieta Inkielewicz-Stepniak, Iwona Int J Nanomedicine Original Research PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs. MATERIALS AND METHODS: AgNPs were synthesized and characterized by transmission electron microscopy, UV-vis spectrometry, thermogravimetric analyses, and dynamic light scattering. We determined the safety and the antimicrobial and anti-inflammatory properties of synthesized AgNPs in an in vitro model of periodontitis. Antimicrobial properties were determined by measuring the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) on reference strains of bacteria and fungi. Human gingival fibroblast (HGF-1), murine macrophage (RAW264.7) and human foetal osteoblast (hFOB1.19) cells were used in the study. Lipopolysaccharide (LPS) was used to induce inflammation. Cytokine levels were measured using an enzyme-linked immunosorbent assay; metalloproteinase expression was measured using Western blotting. RESULTS: The synthesized AgNPs were spherical and narrow-dispersed with an average diameter of 13.4 nm ± 3.0 nm in the case of AgNPs-CHL and 3.72 nm ± 0.72 nm in the case of AgNPs-PEG-MET. Both types of AgNPs were active against bacteria and fungi. AgNPs-CHL proved to be a more potent antimicrobial agent, although they were more cytotoxic than AgNPs-PEG-MET; however, both demonstrated beneficial properties in nontoxic concentrations. AgNPs-CHL and AgNPs-PEG-MET decreased the production of proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Both agents also decreased the levels of metalloproteinases MMP3 and MMP8, which may indicate that they will inhibit tissue degradation. CONCLUSION: AgNPs-CHL and AgNPs-PEG-MET may be possible therapeutic options for PD, as they have antibacterial and anti-inflammatory properties. However, to fully understand the potential of AgNPs, our in vitro findings must be evaluated in an in vivo model. Dove 2022-02-02 /pmc/articles/PMC8820264/ /pubmed/35140461 http://dx.doi.org/10.2147/IJN.S339046 Text en © 2022 Steckiewicz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Steckiewicz, Karol P Cieciórski, Piotr Barcińska, Ewelina Jaśkiewicz, Maciej Narajczyk, Magdalena Bauer, Marta Kamysz, Wojciech Megiel, Elżbieta Inkielewicz-Stepniak, Iwona Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title | Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title_full | Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title_fullStr | Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title_full_unstemmed | Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title_short | Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis |
title_sort | silver nanoparticles as chlorhexidine and metronidazole drug delivery platforms: their potential use in treating periodontitis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820264/ https://www.ncbi.nlm.nih.gov/pubmed/35140461 http://dx.doi.org/10.2147/IJN.S339046 |
work_keys_str_mv | AT steckiewiczkarolp silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT cieciorskipiotr silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT barcinskaewelina silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT jaskiewiczmaciej silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT narajczykmagdalena silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT bauermarta silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT kamyszwojciech silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT megielelzbieta silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis AT inkielewiczstepniakiwona silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis |